Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Brigitte C
BC
Widemann
D058186:Acute Kidney Injury / Q000188:drug therapy*; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000037:antagonists & inhibitors*; D051437:Renal Insufficiency / Q000517:prevention & control*; D011623:gamma-Glutamyl Hydrolase / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D011623:gamma-Glutamyl Hydrolase; D008727:Methotrexate